HOME > What's New Archive > 2018 > Stock Acquisition of Veredus Laboratories Pte. Ltd., a testing Company in Singapore

What's New Archive

Press Release
Stock Acquisition of Veredus Laboratories Pte. Ltd., a testing Company in Singapore
Apr 3, 2018


SEKISUI CHEMICAL CO., LTD. (Headquarters: Osaka; President and Representative Director: Teiji Koge; hereinafter, “SEKISUI CHEMICAL”) has acquired all of the shares in Veredus Laboratories Pte. Ltd. (Headquarters: Singapore, CEO: Rosemary Tan; hereinafter, “VL”), which develops, manufactures and sells molecular analyzers and diagnostic reagents, from companies including Accuron Technologies Limited.

1. Background

While the market scale for diagnostic reagents and analyzers has remained stable in Japan at around 500 billion yen, slight increases have been observed in recent years. Meanwhile, the global market is considered to be approximately 6 trillion yen, and the market is predicted to expand with economic growth in developing countries.

High Performance Plastic Company (President: Keita Kato) of SEKISUI CHEMICAL has positioned life sciences as one of its strategic focus. The company is making efforts to expand the life science field mainly in the medical business through in-vitro diagnostic reagents and analyzers, carried out centrally by its 100% subsidiary, SEKISUI MEDICAL CO., LTD. (Headquarters: Chuo-ku, Tokyo, President and Representative Director: Hideo Tagashira; hereinafter: SEKISUI MEDICAL).

At SEKISUI MEDICAL, in the 5-year midterm management strategy “HIYAKU 2020”*1 which covers FY2016 through FY2020, entering into new markets has been positioned as one of its basic strategy. It aims to cultivate markets in regions such as China and Asia, where market growth is expected going forward.

*1 Refer to press release dated January 14, 2016

2. Reason for stock acquisition

By the incorporation of VL’s unique technology, products and sales channels, the SEKISUI CHEMICAL GROUP will aim to expand its life science field of into a business which has global presence. Specifically, the following two effects are anticipated in particular.

(1) Establishment of ASEAN sales base and sales support system

While VL sells its own products mainly in Singapore, VL will be utilized as a sales base for the ASEAN region. The aim will be to introduce and expand the sales of the diagnostic reagent and analyzer products of the SEKISUI MEDICAL GROUP, which already has a presence in Japan, China and Europe. Sales support system, including response to regional laws and regulations such as product authorization and technological services that satisfy local needs, is essential for such introduction and expansion of sales. The knowledge held by VL, which has developed its business over many years in the ASEAN region, will be utilized to construct such a system.

(2) Business area expansion and creation of technological synergy

SEKISUI MEDICAL has positioned the five fields of clinical chemistry/immunology, blood coagulation, diabetes, POCT and blood collection tubes as focus areas in the diagnostics business, which is the company’s core business. VL has a lineup of molecular biological products on a lab-on-chip platform for the detection of pathogens in various fields. These include tests for tropical infections such as Zika, Malaria and Dengue. Other panels include Influenza subtyping; species differentiation and drug resistance for Mycobacterium tuberculosis; food pathogen tests for bacteria such as salmonella and dysentery bacillus, as well as biosurveillance tests for biological weapons such as anthrax and smallpox. Such technology and products from VL will be incorporated into our life science business to expand the business area and produce technological synergy.

3. Summary of Subsidiary Company Being Transferred (Veredus Laboratories Pte. Ltd.)



Veredus Laboratories Pte. Ltd.


Headquarters address

83 Science Park Drive #04-02 The Curie Singapore 118258



CEO: Rosemary Tan


Principal Business

Development, manufacture and sales of genetic analyzers and diagnostic reagents, etc.



11.777 million Singaporean dollars



June 2003


Main stockholders

Accuron Technologies Limited (51%), STMicroelectonics N.V. (16%), etc.


Latest Business Results

Sales of 9.7 million Singaporean dollars

Operating profit: 1.6 million Singaporean dollars (FY2016)




4. Impact on Business Results

This acquisition has limited affect to the consolidated performance of SEKISUI CHEMICAL for the period ending March 2018.

<Reference (1) SEKISUI MEDICAL Summary>






1-3, Nihonbashi 2-chome, Chuo-ku, Tokyo



President and CEO: Hideo Tagashira


Principal Business:

Diagnostics Business, Pharmaceuticals & Fine Chemicals Business, ADME & Tox. Research Business


Paid in Capital:

1.275 billion yen



April 1, 2008 (previous incarnation as Daiichi Pure Chemicals Co., Ltd. established on July 10, 1947)






39 billion yen (as of March 2017. SEKISUI MEDICAL alone)



https://www.sekisuimedical.jp/(Japnese site)

https://www.sekisuimedical.jp/english/(English site)

<Reference (2) Main measures (M&As etc.) recently implemented by SEKISUI CHEMICAL in the life science (medical) field>

October 2006:

Acquired Daiichi Pure Chemicals Co., Ltd. from Daiichi Pharmaceutical Co., Ltd.

April 2008:

SEKISUI CHEMICAL’s Medical Product Division was merged with Daiichi Pure Chemicals Co., Ltd., and the company name was changed to SEKISUI MEDICAL CO., LTD.


August 2008:

Acquired the US-based in vitro pre-clinical studies contract research organization, XenoTech, LLC.

April 2009:

Acquired the US-based diagnostics business company, American Diagnostica Inc.

February 2011:

Acquired the diagnostic reagent business from US-based Genzyme Corporation, established SEKISUI DIAGNOSTICS, LLC in the United States and started expanding business through the establishment of new corporations in the UK, Canada and Germany, as well as the stock acquisition of a subsidiary.

April 2012:

Merged American Diagnostica Inc. with SEKISUI DIAGNOSTICS, LLC.

December 2015:

Acquired EIDIA Co., Ltd. from Eisai Co., Ltd.

December 2015:


April 2017:

Company merger of SEKISUI MEDICAL CO., LTD. and EIDIA Co., Ltd. (currently: SEKISUI MEDICAL CO., LTD.)


This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.
Page Top